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Abstract:	(202	words)	
Background:	Women	with	antiphospholipid	antibodies	(aPL)	are	at	risk	of	adverse	pregnancy	
outcomes,	 including	 recurrent	 first	 trimester	 pregnancy	 loss	 and	 late	 pregnancy	
complications	 such	 as	 pre-eclampsia,	 HELLP	 syndrome,	 premature	 delivery,	 intrauterine	
growth	 restriction,	 placental	 abruption	 and	 intrauterine	 death.	 Current	 standard	 care	 in	
obstetric	antiphospholipid	syndrome	(APS)	 include	aspirin	and	heparin,	and	has	resulted	 in	
live-birth	 rates	 of	 approximately	 70%.	 However,	 30%	 continue	 to	 have	 pregnancy	
complications.	Hydroxychloroquine	(HCQ)	is	suggested	as	a	new	treatment	approach,	but	no	
randomised	controlled	trials	(RCT)	have	assessed	its	efficacy.		
Aims:	 To	 assess	 pregnancy	 outcome	 in	 women	 with	 aPL	 treated	 with	 HCQ	 vs	 placebo	 in	
addition	to	standard	treatment.			
Methods:	 The	 HYdroxychloroquine	 to	 improve	 Pregnancy	 outcome	 in	 women	 with	
AnTIphospholipid	 Antibodies	 (HYPATIA)	 study	 is	 a	 phase	 IV	 multicentre	 RCT,	 in	 which	
pregnant	women	with	persistent	aPL	will	receive	either	HCQ	or	placebo	in	addition	to	their	
usual	medication.	 The	 primary	 endpoint	 is	 a	 composite	 of	 aPL-related	 adverse	 pregnancy	
outcomes:	 one	 or	 more	 pregnancy	 loss(es)	 (either	 <	 10	 or	 >	 10	 weeks	 of	 gestation)	 and	
premature	 birth	 before	 34	 weeks	 due	 to	 any	 of	 pre-eclampsia,	 eclampsia,	 recognised	
features	of	placental	insufficiency.			
Discussion:	 The	 HYPATIA	 study	 is	 expected	 to	 provide	 evidence	 on	 the	 effect	 of	 HCQ	 in	
pregnant	women	with	persistent	aPL.		
	
Keywords:	 antiphospholipid	 antibodies,	 antiphospholipid	 syndrome,	 obstetric	
antiphospholipid	syndrome,	pregnancy,	hydroxychloroquine		
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Introduction		
Antiphospholipid	 syndrome	 (APS)	 is	 characterised	 by	 the	 presence	 of	 persistent	
antiphospholipid	 antibodies	 (aPL)	 and	 clinical	 manifestations	 such	 as	 thrombosis,	 micro	
vascular	 events	 and/or	 pregnancy	morbidity	 and	mortality	 [1].	 The	 obstetric	morbidity	 in	
APS	 includes	 recurrent	 pregnancy	 first	 trimester	 loss,	 and	 aPL-related	 ischaemic	 placental	
dysfunction	 such	as	pre-eclampsia,	 eclampsia,	HELLP	 syndrome	 (haemolysis,	 elevated	 liver	
function	and	low	platelets),	premature	delivery,	intrauterine	growth	restriction	(IUGR),	along	
with	 intrauterine	 death	 [1].	 The	 aPL	 included	 in	 the	 classification	 criteria	 include	 lupus	
anticoagulant	(LAC),	 immunoglobulin	(Ig)G	and	IgM	anticardiolipin	antibodies	(aCL),	as	well	
as	IgG	and	IgM	anti-β2glycoprotein	I	(aβ2GPI)[1].	
The	 use	 of	 low	 dose	 aspirin	 and	 low	 molecular	 weight	 heparin	 (LMWH)	 is	 the	 current	
standard	 of	 prevention	 of	 aPL-	 related	 obstetric	 complication	 in	 women	 with	 aPL,	 and		
despite	a	limited	body	of	evidence	supporting	this	treatment,	approximately	70%	of	women	
deliver	 a	 live	 viable	 infant	 [2-4].	However,	 30%	of	women	with	 aPL	 continue	 to	have	 aPL-
related	pregnancy	complications.		
The	prevention	of	obstetric	 complications	of	aPL	 therefore	 remains	 suboptimal,	 and	other	
treatment	 options	 have	 been	 explored.	 The	 addition	 of	 first-trimester	 low-dose	
prednisolone	to	conventional	treatment	 improved	the	rate	of	 live	births	 in	refractory	aPL	-
related	 pregnancy	 loss(es)	 up	 to	 61%	 [5].	 Other	 treatments,	 such	 as	 intravenous	 Ig,	 have	
failed	 to	 show	 benefit	 [6,	 7].	 Hydroxychloroquine	 (HCQ)	 in	 APS	 is	 receiving	 increasing	
international	attention,	and	a	group	of	experts	recommended	HCQ	in	addition	to	standard	
treatment	in	those	with	APS	and	with	previous	pregnancy	failure	on	current	treatment	[8].	
Furthermore,	 an	 international	 task	 force	 highlighted	 the	 need	 for	 clinical	 trials	 of	 HCQ	 in	
pregnant	women	with	aPL	and	APS	[9].	Herein	we	will	review	the	available	basic	science	and	
clinical	evidence	for	using	HCQ	in	the	setting	of	aPL.	Moreover,	we	will	present	the	protocol	
for	 the	 first	 randomised	 controlled	 trial	 (RCT)	 of	 HCQ	 versus	 placebo	 in	 pregnant	women	
with	persistent	aPL.		
	
What	is	known	about	HCQ’s	action	in	the	presence	of	aPL:	basic	science	
Chloroquine	and	HCQ	are	weakly	basic	4-aminoquinoline	compounds.	HCQ	is	the	synthetic	
form	of	chloroquine	and	differs	only	by	a	hydroxyl	group	attached	to	a	side	chain	resulting	in	
a	preserved	efficacy	with	a	 less	 toxic	side-effect	profile	 [10].	The	exact	pharmacodynamics	
and	action	of	HCQ	 in	vivo	 remain	to	be	fully	uncovered,	but	most	 likely	multiple	molecular	
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pathways	 are	 involved.	HCQ’s	detailed	effects	 in	 systemic	 lupus	erythematosus	 (SLE)	have	
been	 described	 elsewhere	 [11].	Wallace	 et	 al	 have	 described	 HCQ’s	 ability	 to	 antagonise	
Toll-like	 receptor-mediated	 immune	 response	 activation	 as	 one	 of	 the	 most	 important	
features	 in	 SLE	 [11].	 It	 remains	 unknown	 which	 effects	 of	 HCQ	 are	 important	 in	 the	
immunomodulation	 of	 autoimmune	 diseases	 and	 also	 if	 different	 effects	 are	 required	 in	
different	autoimmune	diseases	[12].	
In	 retrospective	 clinical	 studies,	 HCQ	 was	 associated	 with	 a	 reduction	 in	 the	 risk	 of	
thrombosis	 in	 lupus	patients	and	 is	discussed	below.	The	mechanism	by	which	HCQ	might	
have	 an	 antithrombotic	 effect	 has	 been	 studied	 in	 a	 limited	 way.	 In	 vitro	 studies	 have	
showed	that	HCQ	inhibits	platelet	aggregation	and	the	release	of	arachidonic	acid	from	aPL	
induced	stimulated	platelets	[13].	Furthermore,	Rand	et	al.	showed	that	aPL	can	disrupt	the	
physiological	 anticoagulant	 shield	 of	 annexin	 A5	 (AnxA5),	 leading	 to	 exposure	 of	 pro-
coagulant	 phosphatidylserine	 and	 subsequently	 triggering	 thrombosis.	 As	 a	 novel	 finding,	
the	 group	 could	 show	 that	HCQ	 restores	 the	disruption	of	 natural	 anticoagulant	AnxA5	 in	
patients	with	aPL	[14].	
	
Tissue	factor	(TF)	is	the	key	initiator	of	in	vivo	coagulation	and	has	been	implicated	in		in	the	
pathogenesis	 of	APS	 [15].	 The	ability	 of	 aPL	 to	 induce	TF	expression	was	demonstrated	 in	
vitro	 studies	 using	 serum	 samples	 from	 patients	 with	 purified	 aPL,	 which	 were	 added	 to	
cells,	 showing	up-regulation	of	TF	on	monocytes	 [16,	17],	neutrophils	 [18]	and	endothelial	
cells	 [19].	 A	 number	 of	 investigators	 have	 found	 that	 serum,	 plasma,	 purified	 total	 IgG,	
antiB2GPI	 from	 APS	 patients	 increases	 TF	 expression	 and	 pro-coagulant	 activity	 on	
monocytes	 [20-22].	 Lopez-	 Pedrera	 et	 al	 showed	 that	 aCL	 IgG	 stimulate	 TF	 expression	 on	
circulating	monocytes,	acting	 through	 intracellular	pathways	 including	NFKappaB	and	MAP	
kinases	[17].		In	mice	with	aPL-induced	fetal	loss,	neutrophils	in	turn	can	express	TF	through	
aPL–induced	complement	activation	[23].		
We	have	recently	assessed	the	effect	of	using	HCQ	in	patients	with	aPL	and	APS	on	plasma	
biomarkers	including	soluble	TF,	which	has	been	shown	to	be	increased	in	patients	with	APS	
[24].	We	showed	that	the	use	of	HCQ	was	effective	to	decrease	soluble	TF	levels	in	patients	
with	aPL	and	APS	 	12	weeks	after	 the	commencement	of	HCQ	compared	 to	baseline.	This	
may	be	a	mechanism	contributing	HCQ’s	antithrombotic	effect	[24].		
Results	from	experiments	in	a	murine	model	by	Edwards	et	al.	show	that	HCQ	has	the	ability	
to	reverse	aPL-induced	thrombosis	[25].	The	group	observed	that	aPL-injected	mice	treated	
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with	 HCQ	 had	 a	 significantly	 reduced	 thrombus	 size	 and	 that	 thrombus	 duration	 was	
reduced	compared	to	mice	treated	with	placebo	[25].	 In	vitro	 studies	showed	that	aPL	are	
directly	 pathogenic	 towards	 trophoblast	 cells,	 which	 is	 a	 mechanism	 cited	 as	 a	 possible	
cause	of	recurrent	first	 trimester	pregnancy	 loss(es)	[26].	 	 In	vitro	studies	have	shown	that	
HCQ	 reversed	 the	 aPL-induced	 inhibition	 of	 the	 chemokine	 interleukin	 6	 (IL-6)	 [27].	 IL-6	
released	by	first	trimester	trophoblast	cells	had	been	shown	to	drive	trophoblast	migration	
(a	vital	process	for	implantation)	in	previous	studies	by	the	same	group	[28].		
	
We	 and	 others	 have	 hypothesised	 that	 angiogenic	 molecules	 may	 play	 a	 role	 in	 the	
pathogenesis	of	obstetric	APS,	in	light	of	their	role	in	other	placental	dysfunction	conditions	
such	as	pre-eclampsia	[29,	30].	Elevated	levels	of	circulating	soluble	fms-like	tyrosine	kinase	
1	 (sFlt1)	 is	 thought	 to	cause	 the	maternal	expression	of	pre-eclampsia.	 Levels	of	 sFlt1	and	
proangiogenic	 factors	 (such	 as	 vascular	 endothelial	 growth	 factor	 (VEGF)	 and	 placental	
growth	factor	(PlGF))	have	been	proposed	as	predictors	of	preeclampsia	 in	healthy	women	
[29,	 30].	 In	 492	pregnant	women	 from	 the	prospective	multicentre	 cohort,	 the	PROMISSE	
cohort	 (PRedictors	 of	 pRegnancy	 outcome:	 BioMarkers	 In	 antiphospholipid	 Syndrome	 and	
Systemic	lupus	Erythematosus),	Kim	et	al.	found	that	the	circulating	pro	and	anti	angiogenic	
factors	 such	 as	 sFlt1,	 PlGF	 and	 soluble	 Endoglin	 (sEng)	measured	 between	week	 12-15	 of	
gestation	were	predictive	of	adverse	pregnancy	outcomes	in	women	with	SLE	and	aPL	[31].		
	
Current	 available	 evidence	 suggests	 that	 aPL	 can	 affect	 the	 maternal	 side	 of	 developing	
placenta	 by	 reacting	 with	 endometrial	 cells	 in	 the	 decidua,	 by	 which	 they	 induce	 a	 pro-
inflammatory	phenotype	and	 interfere	with	 the	physiological	 implantation	process	causing	
first	 trimester	 loss	 [32].	These	mechanisms	are	also	thought	to	play	a	role	 in	the	failure	of	
adequate	vascularisation	of	developing	placenta,	ultimately	resulting	 in	complications	such	
as	pre-eclampsia.	We	wished	to	explore	the	possible	beneficial	effect	of	HCQ	on	angiogenic	
biomarkers,	as	this	has	not	been	explored	before.	
	
	
Some	studies	support	the	hypothesis	 that	the	complement	system	is	activated	and	plays	a	
role	in	the	pathogenesis	of	thrombotic	and	obstetric	APS	[23,	33-36].	Our	group	and	others	
have	 previously	 confirmed	 complement	 activation	 in	 patients	 with	 isolated	 aPL	 and	 APS	
(thrombotic	 and	obstetric	APS)	 compared	 to	healthy	 controls	 [37,	38].	Our	most	 recent	 in	
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vivo	 results	assessing	the	effect	of	HCQ	on	complement	activation	markers	C3-des-Arg	and	
Bb	 in	 HCQ	 naive,	 non-pregnant	 aPL	 and	 APS	 patients	 at	 baseline	 and	 12	weeks	 after	 the	
commencement	of	HCQ	did	not	show	any	significant	change	in	these	values	[24].		
	
In	 mice	 exposed	 to	 complement	 inhibitors	 and	 knockout	 mice	 which	 have	 complement	
deficiencies	there	is	inhibition	of	foetal	loss	and	growth	restriction	mediated	by	aPL	[23,	33],	
and	also	less	aPL	induced	thrombus	[34,	35].	Bertolaccini	et	al	showed	a	possible	protective	
effect	HCQ	of	in	a	model	of	aPL-induced	foetal	loss	[39].	In	their	mouse	model,	the	fetuses	
died	 in	 50%	 of	 pregnant	 aPL-injected	mice	 and	 the	 survivors	 were	 growth-restricted	 and	
with	 smaller	 placentas	 compared	 to	 control	 mice.	 The	 administration	 of	 HCQ	 to	 mice	
exposed	to	aPL	prevented	 fetal	death,	 increased	placental	and	 fetal	weight	and	decreased	
placental	 superoxide	production	 (a	marker	of	oxidative	 stress)	 [39].	 In	 addition,	 the	group	
reported	HCQ-induced	 complement	 inhibition	 in	APS	patient	 serum,	 specifically	 looking	 at	
the	common	pathway	complement	activation	product	C5a-des-Arg	after	receiving	6.5	mg/kg	
HCQ	for	6	months	[39].	 
	
	At	an	intracellular	level,	in	vitro	studies	show	that	aPLs	can	induce	endosomal	NADPH	(NOX)	
in	 endothelial	 cells	 and	 monocytes	 [40,	 41].	 NOX	 is	 an	 enzyme	 complex	 involved	 in	 pro-
inflammatory	 signalling	 pathways	 [12].	Muller-Calleja	 et	 al	 recently	 published	 first	 in	 vitro	
data	suggesting	that	HCQ	significantly	reduces	the	induction	of	endosomal	NOX,	which	leads	
to	a	 reduction	of	downstream	gene	activation	 [12].	This	 ’protective’	mechanism	of	HCQ	 in	
preventing	monocyte	activation	was	confirmed	in	mice	injected	with	human	aPL	[12].		
	
What	is	known	about	HCQ’s	use	in	patients	with	systemic	lupus	erythematosus	and	APS:	
clinical	studies			
HCQ	 is	 traditionally	an	antimalarial	drug	and	has	since	 the	1950’s	been	widely	used	 in	 the	
treatment	of	patients	with	rheumatoid	arthritis	(RA)	or	systemic	connective	tissue	diseases	
such	as	SLE.	HCQ	was	the	first	drug	licensed	for	the	treatment	of	SLE,	and	is	one	of	the	two	
currently	licensed	medications	in	SLE	[42].	The	efficacy	of	HCQ	in	patients	with	SLE	has	been	
well	 described.	 A	 cohort	 study	 of	 150	 SLE	 patients	 showed	 that	 it	 improves	 damage	 free	
survival	 [43],	 whereas	 data	 of	 518	 SLE	 patients	 from	 the	 observational	 LUMINA	 cohort	
showed	that	its	use	is	associated	with	a	reduced	accrual	of	new	disease	damage	[44].	Ruiz-
Irastorza	 performed	 a	 prospective	 observational	 cohort	 of	 232	 patients,	 showing	 an	
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improved	survival	 in	SLE	patients	taking	HCQ	[45].	The	use	of	HCQ	in	SLE	is	also	associated	
with	a	 reduced	 risk	of	SLE	 flares.	The	Canadian	Hydroxychloroquine	Study	Group	 reported	
from	 their	 randomised	 controlled	 trial	 (RCT),	 that	 discontinuation	 of	 HCQ	was	 associated	
with	a	2.5x	relative	risk	of	a	clinical	lupus	flare	and	that	the	risk	of	severe	disease	flare	was	
significantly	higher	in	patients	who	had	HCQ	discontinued	[46].		
The	 antithrombotic	 effects	 of	 HCQ	 in	 patients	 with	 SLE	 was	 reported	 in	 data	 from	 the	
LUMINA	cohort.	In	univariate	analysis,	including	442	SLE	patients	with	aPL	of	whom	46	were	
identified	having	51	recorded	thrombotic	events	(over	1446	visits	followed	over	a	mean	of	
88	months),	a	protective	effect	of	HCQ	use	was	demonstrated	(odds	ratio	[OR],	0.536).	This	
finding	is	in	line	with	an	observational	prospective	cohort	study	of	232	SLE	patients,	in	which	
Cox	regression	analysis	showed	that	HCQ	use	was	associated	with	a	reduced	risk	thrombosis	
(seven	events	occurred	while	patients	were	taking	HCQ,	7	further	events	happened	after	the	
patient	had	stopped	HCQ	whereas	28	events	were	reported	in	patients	who	had	never	taken	
HCQ,	so	yielding	a	hazard	ratio	[HR]	of	0.28)	[45].	Likewise,	the	antithrombotic	effect	of	HCQ	
could	also	be	demonstrated	 in	several	other	cohort,	case-control	and	retrospective	studies	
[11].	 Moreover,	 the	 safe	 use	 of	 HCQ	 in	 pregnancy	 and	 lactation	 has	 been	 extensively	
documented	 and	 systematically	 reviewed	 [47-49].	 Most	 data	 on	 the	 use	 of	 HCQ	 in	
pregnancy	stems	from	patients	with	SLE.	Treatment	of	pregnant	patients	with	SLE	was	first	
described	more	 than	 three	 decades	 ago,	 and	 national	 and	 international	 clinical	 guidelines	
now	 recommend	 using	 HCQ	 in	 pregnant	 women	 with	 underlying	 autoimmune	 diseases	
requiring	immunomodulation	[50,	51].			
The	role	of	HCQ	in	APS	is	currently	being	investigated	in	thrombotic	and	obstetric	APS.	In	a	
prospective	 non-randomised	 study	 of	 40	 patients	 with	 primary	 thrombotic	 APS	 without	
underlying	SLE,	Schmidt-Tanguy	et	al.	studied	the	effect	of	400	mg	HCQ	in	addition	to	oral	
anticoagulation	 with	 vitamin	 K	 antagonists	 (VKA),	 target	 INR	 2-3.	 None	 of	 the	 patients	
receiving	HCQ	along	with	 standard	 anticoagulation	had	 recurrent	 thromboembolic	 events,	
whereas	 30%	 in	 the	 control	 group	 experienced	 a	 recurrent	 event	 (p=0.0086)	 [52].	
Unfortunately,	 the	 first	 RCT	 assessing	 the	 role	 of	 HCQ	 role	 as	 primary	 prophylaxis	 in	 aPL	
positive	patients	has	recently	been	terminated	due	to	manufacturing	shortage	[53].		
	
In	 retrospective	 studies	of	 pregnant	patients	with	 aPL	 and	or	APS,	we	and	others	 showed	
that	HCQ	is	a	candidate	for	preventing	aPL-related	adverse	pregnancy	outcomes	[54,	55].	In	
a	 retrospective	 multicentre	 cohort	 consisting	 of	 30	 APS	 patients	 (and	 35	 pregnancies),	
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Mekinian	 et	 al	 reported	 that	 HCQ	 was	 associated	 with	 fewer	 first	 trimester	 miscarriages	
(pregnancy	 losses	 decreased	 from	 81%	 to	 19%,	 p<0.05)	 and	 improved	 live	 birth	 rates	 in	
refractory	obstetric	APS	to	78%	(p<0.05)[54].	In	our	retrospective	observational	cohort	study	
of	 96	women	with	 170	 pregnancies,	 we	 also	 showed	 that	 HCQ	 treatment	was	 associated	
with	a	higher	rate	of	live	births	(67%	in	HCQ	treated	vs.	57%	in	untreated	patients,	p=0.05)	
and	a	lower	prevalence	of	pregnancy	morbidity	(47%	vs.	63%,	p=0.004).	Pregnancy	duration	
was	longer	in	patients	receiving	HCQ	compared	to	those	who	did	not	receive	HCQ	(median	
27.6	weeks,	range	[6-40]	versus	21.5	weeks	[6-40],	p=0.03)	and	foetal	losses	beyond	the	10	
weeks	of	gestation	were	less	frequent	in	women	who	were	treated	with	HCQ	(2%	vs.	11%,	
p=0.05).	Moreover,	 ischaemic	 placental	mediated	 complications	 (pre-eclampsia,	 eclampsia	
and	foetal	growth	restriction	(FGR)	were	 less	prevalent	 in	HCQ	treated	women	than	 in	the	
control	 group	 (2%	 vs	 10.9%,	 p=0.05).	 There	 was	 a	 significantly	 higher	 rate	 of	 women	
undergoing	spontaneous	vaginal	 labour	 in	HCQ	women	compared	 to	women	without	HCQ	
treatment	 (37.3%	 vs.	 14.3%,	 p=0.01).	 The	 association	 of	 HCQ	 with	 the	 absence	 of	 aPL-
related	complications	 in	pregnancy	was	confirmed	 in	multivariate	analysis	 (OR	2.2;	95%	CI	
1.2-136.1;	p=0.04)	[55].	However,	the	design	of	this	retrospective	study	was	suboptimal,	as	
the	two	groups	were	heterogeneous,	with	higher	prevalence	of	SLE	amongst	those	receiving	
HCQ.	 These	 clinical	 and	 animal	 studies,	 as	 well	 as	 in	 vitro	 and	 ex	 vivo	 data,	 suggest	 a	
potential	role	of	HCQ	in	reducing	pregnancy	morbidity	and	mortality	in	women	with	aPL.	In	
view	of	 all	 of	 the	available	evidence,	we	proposed	HYPATIA	 study	 (HYdroxychloroquine	 to	
improve	 Pregnancy	 outcome	 in	 women	 with	 AnTIphospholipid	 Antibodies)	 which	 is	 a	
randomised	controlled	multicentre	trial	of	HCQ	versus	placebo	in	women	with	persistent	aPL	
planning	 for	 pregnancy.	 Our	 hypothesis	 is	 that	 HCQ	 may	 improve	 aPL-related	 pregnancy	
complications	[56].		
	
Methods		
Study	design		
The	HYPATIA	study	is	an	investigator	initiated		multi-centre,	double	blind	RCT	of	women	with	
persistent	aPL	planning	to	fall	pregnant.	Patients	will	be	randomised	to	HCQ	or	an	identically	
looking	placebo	in	addition	to	their	usual	medication.			
Once	a	woman	is	enrolled	into	the	HYPATIA	study,	she	will	be	attending	3	monthly	follow	up	
visits	 until	 she	 falls	 pregnant	 (defined	 as	 pre-pregnancy	 visits).	 Patients	will	 be	 starting	 to	
take	the	investigational	medicinal	product	(IMP)	as	soon	as	they	are	randomised	(i.e.	before	
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conception).	 If	 no	pregnancy	 is	 achieved	within	12	months,	 she	will	 be	excluded	 from	 the	
study.	These	visits	coincide	with	 the	usual	 routine	 follow	up	visits.	On	these	visits	 the	 IMP	
will	be	repeatedly	dispensed	and	compliance	will	be	assessed.	All	data	will	be	collected	in	an	
electronic	case	record	file.			
When	 a	 woman	 falls	 pregnant,	 she	 will	 contact	 the	 study	 team	 and	 attend	 her	 first	
pregnancy	 visit	 (first	 trimester	 visit).	At	 this	 visit	 a	 new	 trial	medication	will	 be	dispensed.	
Follow	 up	 visits	 for	 the	 HYPATIA	 study	 purpose	 will	 be	 scheduled	 once	 every	 trimester	
(defined	as	1st,	2nd	and	3rd	 trimester	visits).	Nevertheless,	 if	 the	participant	 required	closer	
monitoring,	 she	 will	 be	 followed	 up	 accordingly	 as	 per	 standard	 of	 care.	Women	 will	 be	
instructed	to	stop	trial	medication	on	the	day	of	delivery	and	will	be	asked	to	hand	 in	 the	
rest	 of	 the	 trial	medication	 at	 their	 post-partum	 follow	up.	 The	 post-partum	 visit	 shall	 be	
completed	6	weeks	post-partum.	
Patient	recruitment	
Potentially	eligible	women	will	be	identified	in	routine	outpatient	clinics	in	our	participating	
sites,	 which	 include:	 Guy’s	 and	 St	 Thomas’	 NHS	 Foundation	 Trust,	 London,	 UK;	 Imperial	
College	 Health	 Care	 NHS	 Trust,	 London,	 UK;	 University	 College	 London	 NHS	 Foundation	
Trust,	 London,	 UK;	 Liverpool	 Women’s	 Hospital	 NHS	 Foundation	 Trust;	 Oxford	 University	
Hospitals	 NHS	 Foundation	 Trust,	 Oxford,	 UK;	 Academic	 Medical	 Center	 Amsterdam,	 the	
Netherlands;	 University	 Hospital	 Torino,	 Italy;	 University	 Hospital	 Copenhagen,	 Denmark.	
Patients	will	 receive	 full	 information	 about	 the	HYPATIA	 study,	 and	 if	 they	 decide	 to	 take	
part,	 written	 informed	 consent	will	 be	 obtained.	 Patients	will	 have	 as	much	 time	 as	 they	
need	 to	 consider	 their	 participation.	 Provided	 all	 eligibility	 criteria	 are	 fulfilled,	 study	
randomisation	 can	 be	 undertaken	 and	 the	 investigational	medicinal	 product	 (IMP)	will	 be	
dispensed.			
Potential	participants	will	be	identified	by	their	physician	during	routine	outpatient	visits	to	
the	trial	sites.	The	HYPATIA	study	visit	assessment	schedule	is	outlined	in	Figure	1.		
Inclusion	criteria:	
1. Women	with	known	persistent	aPL	(ie.	isolated	persistent	aPL	or	APS)	who	are	planning	
pregnancy	and	consent	to	participate.		
Exclusion	criteria:	
1. Women	who	are	already	pregnant		
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2. Allergy	 or	 adverse	 event	 to	 HCQ.	 Hypersensitivity	 to	 the	 active	 substance,	 4-
aminoquinoline	or	any	of	the	compounds	of	the	IMP	or	placebo.		
3. Current	treatment	with	HCQ	
4. Age	<	18	and	>	45	years	
5. Body	weight	<	45	kg		
6. Psoriasis	
7. Uncontrolled	epilepsy	
8. Anti-Ro	antibodies	
9. Renal	replacement	therapy	
10. Other	severe	active	co-morbidities	(HIV,	hepatitis	B)	
11. Porphyria		
12. History	of	retinopathy		
13. History	of	galactose	intolerance,	lactase	deficiency	or	glucose-galactose	malabsorption	
14. Participation	in	any	other	IMP	trial	at	the	time	of	consent		
15. Previous	pregnancy	failure	on	HCQ	
	
Laboratory	 assessment	 for	 aPL	 diagnosis:	 For	 the	 purpose	 of	 the	 HYPATIA	 study	 aPL	
positivity	is	defined	by	the	presence	of	a	positive	test	for	anticardiolipin	antibodies	(IgG/IgM	
isotypes	 >	 95th	 percentile)	 and/or	 lupus	 anticoagulant	 and/or	 anti-	 beta	 2	 glycoprotein-I	
(IgG/IgM	 isotypes	 >	 95th	 percentile),	 on	 two	or	more	 consecutive	 occasions	more	 than	 12	
weeks	 apart.	 All	 participating	 sites	 will	 be	 expected	 to	 have	 established	 their	 own	 95th	
percentile,	and	data	on	absolute	values	(for	aCL	and	anti-	beta	2	glycoprotein-I),	 lower	and	
upper	normal	value	will	be	collected	in	the	electronic	database.	aPL	are	assessed	according	
to	standard	established	methods	[57,	58].		
	
Duration	of	trial	
The	HYPATIA	study	will	last	for	a	total	of	36	months,	which	includes	recruitment	and	follow-
up	of	patients.		The	end	of	the	trial	is	defined	as	database	lock.	Each	individual	will	remain	in	
the	study	as	long	as	their	time	to	conception	(up	to	maximum	12	months),	their	full	length	of	
pregnancy	until	 delivery.	 In	 total	 328	pregnant	women	 (sample	 size	 calculation	 is	 detailed	
below)	will	be	included	in	the	study.	The	trial	flow	chart	is	summarised	in	figure	2.		
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Primary	outcome	measures		
The	 primary	 endpoint	 is	 a	 composite	 of	 three	 principal	 aPL-related	 adverse	 pregnancy	
outcomes:	one	or	more	pregnancy	loss(es)	(either	<	10	weeks	gestation	or	beyond	10	weeks	
of	 gestation	 of	 a	 morphologically	 normal	 foetus	 documented	 by	 ultrasound	 or	 by	 direct	
examination	of	the	foetus)	and	premature	birth	of	a	morphologically	normal	neonate	before	
34	 weeks	 due	 to	 any	 of	 pre-eclampsia,	 eclampsia,	 recognised	 features	 of	 placental	
insufficiency.		
Premature	 birth	 for	 other	 reasons	 will	 not	 be	 included.		 The	 components	 of	 the	 primary	
endpoint	will	each	be	presented	as	secondary	endpoints	(below).	
Secondary	outcomes	measures		
The	 pre-defined	 secondary	 endpoints	 include:	 1.	 Pregnancy	 loss	 <	 10	 weeks	 gestation,	 2.	
Pregnancy	loss	>	10th	week	of	gestation	of	a	morphologically	normal	foetus	documented	by	
ultrasound	or	by	direct	examination	of	 the	foetus,	3.	Premature	birth	of	a	morphologically	
normal	neonate	<	34	weeks	due	to	any	of	pre-eclampsia,	eclampsia,	recognized	features	of	
placental	 insufficiency,	 4.	 Gestational	 age	 at	 delivery,	 5.	 Birth	 weight,	 6.	 Delivery	 by	
Caesarean	 section,	 7.	 Apgar	 score	 <	 7	 at	 5	 min,	 8.	 Neonatal	 morbidity	 (bleeding	 or	
thrombotic	 complications,	 infections,	 congenital	 abnormalities),	 9.	 Days	 to	 hospital	
discharge	 following	delivery	 (mother	&	child),	10.	Thrombotic	events	 in	 the	mother	during	
pregnancy	and	6	weeks	post-partum	and	11.	Days	of	neonate	in	special	care.		
Suspected	unexpected	serious	adverse	reactions	(SUSARs)	and	other	serious	adverse	events	
(SAEs)	will	be	reported	to	the	regulatory	authorities	and	the	research	ethics	committees,	as	
appropriate.	All	SAE	reports	received	from	the	study	sites	will	be	reviewed	by	independent	
medically	qualified	staff.	
SAEs	 that	 do	 not	 require	 reporting:	 Pregnancy	 itself	 is	 well	 known	 to	 potentially	 causing	
nausea	and	tiredness	due	to	several	physiological	adjustments	of	the	body	especially	in	the	
first	 trimester.	 Any	 symptoms	 thought	 to	 be	 related	 to	 the	 physiological	 changes	 in	
pregnancy	do	not	require	reporting.		
In	patients	with	aPL	we	expect	pregnancy	complications.	Therefore,	aPL	related	pregnancy	
complications,	 such	 as	 miscarriage	 <	 10	 weeks’	 gestation,	 miscarriage	 >	 weeks	 10,	
premature	 birth	 <	 34	 weeks	 due	 to	 pre-eclampsia,	 eclampsia	 or	 fetal	 growth	 restriction	
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(FGR)	and	stillbirth	shall	not	be	reported	as	SAE.	For	these	events	we	have	designed	a	special	
section	in	the	electronic	database	‘adverse	pregnancy	outcomes’,	which	shall	be	completed	
in	this	case.	Any	other	adverse	events	will	be	reported.		
Randomisation		
Randomisation	will	be	performed	by	an	 independent	 individual	at	King’s	Clinical	Trials	Unit	
(King’s	 CTU),	 using	 a	 computer-based	 minimisation	 process,	 adjusting	 for	 thrombosis	
(yes/no),	previous	adverse	pregnancy	outcomes	(yes/no)	and	previous	pregnancy	(yes/no).		
The	 investigators	 and	 trial	 subjects	will	 remain	 blinded	 to	 treatment.	 The	 trial	 pharmacist	
will	be	blinded	too.	Unique	pack	numbers	for	the	trial	medication	will	be	generated	for	the	
active	and	placebo	products	and	will	be	sent	with	randomisation	emails.	The	trial	statistician	
will	know	only	A	vs	B,	with	the	meaning	of	A	&	B	held	by	King's	CTU.	
	
Statistical	analysis		
Sample	size		
The	sample	size	was	calculated	based	on	our	audit	data.	Retrospective	data	from	St	Thomas’	
Hospital	 showed	 that	 treatment	with	 HCQ	was	 associated	with	 a	 higher	 rate	 of	 live	 birth	
(67%	 in	women	with	 SLE	 and	 aPL	 treated	with	 HCQ	 versus	 57%	 in	women	 in	 the	 control	
group	p=0.05)	and	a	lower	prevalence	of	aPL	related	pregnancy	morbidity	(47%	versus	63%	
p=0.004)[8].	The	trial	is	powered	to	detect	a	16%	reduction	in	pregnancy	morbidity,	which	is	
the	 main	 outcome	 of	 the	 study	 (total	 sample	 size	 328).	 A	 minimum	 of	 328	 women	 will	
therefore	be	 randomised.	The	calculation	was	made	on	 the	 following:	 significance	alpha	=	
0.05,	power	1-beta	80%,	percentage	cross	5%.		
	
Primary	 statistical	 analysis:	 Percentages	 in	both	 arms	of	 the	 study	will	 be	 compared	using	
binomial	 regression	 with	 a	 log	 link,	 adjusting	 for	 the	 minimization	 variables	 to	 give	 risk	
ratios.		Risk	differences	will	be	estimated	similarly.		Continuous	measures	will	be	compared	
using	 linear	 regression	 adjusting	 for	minimization	 variables	 and	 baseline	measurement	 of	
the	outcome	(where	available).		Estimates	will	be	given	with	95%	confidence	intervals.		
Results	will	be	considered	significant	at	the	5%	level.	However,	attention	will	be	paid	to	the	
totality	of	results	and	the	exact	size	of	the	P-value.		Smaller	values	will	be	treated	as	stronger	
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evidence	against	the	null	hypothesis.	The	intention-to-treat	principle	will	be	followed	in	the	
main	 analysis,	 but	 a	 secondary	 per-protocol	 analysis	 will	 also	 be	 performed	 to	 provide	
additional	information	on	the	nature	of	the	treatment	effect.		
Three	subgroup	analyses	are	planned:	by	previous	thrombosis;	previous	adverse	pregnancy	
outcomes;	previous	pregnancy.		In	each	case,	the	primary	outcome	will	be	analysed	in	each	
subgroup,	and	an	interaction	test	carried	out	for	evidence	of	a	difference	in	treatment	effect	
between	the	groups.	
No	formal	interim	analyses	are	planned.		The	Data	Monitoring	Committee	will	aim	to	meet	
in	person	at	least	every	6	months,	and	will	consider	the	results	so	far.		They	are	empowered	
to	 request	 that	 the	 trial	 stops	 if	 there	 is	 overwhelming	 evidence	 for	 or	 against	 one	
treatment,	such	that	to	randomise	further	patients	would	be	unethical.	
Competent	 authority	 approval	 in	 the	 UK	 has	 passed	 the	 initial	 assessment	 and	 ethics	
approval	 is	 currently	 awaited.	 As	 a	 European	 multicentre	 trial	 we	 are	 following	 the	
‘voluntary	harmonisation	procedure’[59].		
	
Discussion		
We	 hypothesise	 that	 the	 addition	 of	 HCQ	 to	 the	 standard	 of	 care	 treatment	 in	 pregnant	
women	 with	 aPL	 will	 improve	 aPL-related	 adverse	 pregnancy	 outcomes.	 Current	 data	 to	
suggest	 a	 role	 of	 HCQ	 in	 these	 patients	 is	 inadequate;	 hence,	 we	 have	 designed	 an	
adequately	powered	RCT	[54,	55].		
We	 have	 shown	 that	 with	 a	 rigorously	 applied	 local	 protocol	 around	 70%	 of	 pregnant	
women	 with	 aPL/APS	 will	 deliver	 a	 viable	 infant	 [2].	 The	 current	 management	 includes	
LMWH	 and/or	 low-dose	 aspirin.	 As	mentioned	 above,	 this	 does	 not	 prevent	 all	maternal,	
foetal	 and	 neonatal	 complications.	 Our	 retrospective	 study	 suggests	 that	 HCQ	 has	 a	
beneficial	 effect	 in	 women	 with	 aPL,	 as	 the	 treatment	 with	 HCQ	 was	 associated	 with	 a	
higher	 rate	 of	 live	 births	 (67%	 vs.	 57%,	 p=0.05)	 and	 a	 lower	 prevalence	 of	 aPL-related	
pregnancy	 morbidity	 (47%	 vs.	 63%,	 p=0.004)	 [55].	 Despite	 the	 heterogeneity	 in	 the	 two	
groups	 in	 terms	of	SLE	prevalence	and	previous	pregnancy	history,	our	results	support	 the	
concept	 that	women	with	aPL	may	benefit	 from	 treatment	with	HCQ	during	pregnancy	 to	
improve	pregnancy	outcome.		
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We	have	also	conducted	a	systematic	review	of	the	evidence	of	HCQ	in	obstetric	APS,	which	
confirmed	 a	 lack	 of	 evidence	 [8].	 We	 therefore	 performed	 an	 expert-based	 clinical	
judgement	 consensus,	 which	 is	 an	 accepted	 approach	 to	 address	 a	 specific	 and	 clinically	
relevant	question	in	an	area	were	best	clinical	practice	is	uncertain.	The	experts	agreed	that	
HCQ	could	be	considered	in	selected	cases	of	patients	with	obstetric	APS	or	after	failure	of	
standard	 treatment	with	 aspirin	 and	 any	 heparin-based	 agent.	Moreover,	 the	majority	 of	
experts	 considered	 adding	 HCQ	 in	 specific	 scenarios,	 such	 as	 women	 with	 previous	
thrombosis	or	previous	ischemic	placental	medicated	complications	[8]	.		
The	ideal	RCT	to	answer	the	question	of	the	benefit	of	HCQ	in	pregnancy	in	those	with	aPL,	
would	 be	 to	 investigate	 women	 with	 refractory	 obstetric	 APS,	 i.e.	 those	 who	 have	 failed	
conventional	treatment,	and	then	to	randomise	this	group	to	HCQ	versus	placebo.	However,	
after	reviewing	our	patient	group	and	discussing	with	all	our	trial	centres,	we	calculated	that	
it	would	take	10	years	to	recruit	adequate	women	to	a	study	of	this	design.	We	have	hence	
chosen	to	study	women	with	aPL	rather	than	women	with	refractory	obstetric	APS,	because	
it	not	only	practically	feasible	but	also	supported	by	the	results	of	our	previous	retrospective	
study.		
Some	may	 argue	 that	 that	 the	 inclusion	 of	 women	with	 aPL	 above	 the	 95th	 percentile	 as	
opposed	 to	 the	 defined	 99th	 percentile	 in	 the	 Miyakis	 criteria	 is	 a	 fault	 in	 the	 study	 [1].	
However,	 it	 is	 our	 and	 others	 experience,	 that	 ‘low	 level	 aPL	 are	 highly	 relevant	 in	 the	
setting	 of	 obstetric	APS	 [60,	 61].	 This	 is	 in	 line	with	 the	 observation	of	 Ruffatti	 et	 al,	 that	
women	with	purely	obstetric	APS	have	lower	aCL	antibody	titres	compared	to	patients	with	
thrombotic	 APS	 [62].	Moreover,	 retrospective	 data	 and	 data	 from	 a	 cohort	 study	 suggest	
that	low-titre	aCL,	defined	as	those	between	the	95th	and	99th	percentiles,	are	still	of	clinical	
significance	for	women	with	obstetric	APS	[63,	64].	
 
Although	 this	 study	 includes	 women	 planning	 to	 fall	 pregnant,	 and	 will	 therefore	 be	
perceived	by	some	as	a	difficult	study.	However	some	of	our	HYPATIA	study	team	members	
have	 experience	 in	 successfully	 conducting	 RCT’s	 in	 which	 women	 were	 recruited	 pre-
conceptionally[65].	We	are	 involving	 centres	 that	are	expert	 tertiary	 centres	 for	managing	
women	 with	 aPL	 and	 managing	 them	 preconception	 and	 throughout	 pregnancy.	
Recruitment	estimates	of	number	of	patients	that	will	be	entered	into	the	study	have	been	
obtained	 from	 each	 centre	 and	 exceed	 the	 proposed	 number	 by	 about	 20%	 and	we	 fully	
expect	completion	of	the	study	in	the	allotted	time.	
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HYPATIA	 is	 the	 first	 trial	 to	 randomise	 HCQ	 versus	 placebo	 in	 pregnant	 women	 with	
persistent	antiphospholipid	antibodies	and	our	results	will	provide	an	evidence-base	for	the	
decision	to	use	of	HCQ	in	these	patients.		
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